🇺🇸 FDA
Pipeline program

human cord blood-derived mononuclear cells (HCB-MNCs)

2022-SR-752

Unknown mab active

Quick answer

human cord blood-derived mononuclear cells (HCB-MNCs) for Refractory Diabetic Foot is a Unknown program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Refractory Diabetic Foot
Phase
Unknown
Modality
mab
Status
active

Clinical trials